-64%

est. 2Y upside i

HealthcareSeries A

Medicinal Chemistry powered by Machine Learning

Rank

#1819

Sector

AI Drug Discovery / Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

PostEra operates in the high-potential AI drug discovery sector, validated by over $1Bn in partnerships with major pharma like Pfizer and Amgen.

Last updated: March 10, 2026

Bull (25%)+300%

PostEra successfully advances multiple partnered programs into clinical trials, leading to significant milestone payments and attracting a large Series C round at a $1B+ valuation, representing a 300% upside from current estimates. The company also progresses its internal pipeline, demonstrating the Proton platform's superior efficacy.

Base (25%)+60%

PostEra continues to execute on existing partnerships, hitting some preclinical milestones, but clinical progress is slower than hoped. Revenue grows steadily to $20M-$30M, and they raise a Series B/C at a modest step-up to a $400M valuation, representing a 60% upside.

Bear (50%)-70%

Key partnered programs fail to meet preclinical milestones, or a major incumbent launches a directly competing and superior platform, leading to a loss of competitive edge. The company struggles to secure new partnerships or raise further capital, resulting in a down round or acquisition at a $75M valuation, wiping out 70% of current estimated value for common shareholders.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Investors hold $26.2M in liquidation preferences ahead of common shareholders. In an exit at or below $26.2M, common shareholders would get little to nothing.

Dilution Risk

high

As a Series A company with high capital intensity, multiple future funding rounds are highly likely, leading to significant dilution for existing common shareholders.

Secondary Liquidity

none

As an early-stage private company, there is currently no active secondary market for PostEra's equity.

Business — 1 role

Software Engineering — 1 role

View all 2 open roles at PostEra →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on PostEra's data — designed to show you've done your homework.

  • 1

    “Given the significant incumbent threat from large pharmaceutical companies developing internal AI capabilities and other well-funded AI drug discovery platforms like Exscientia, how does PostEra plan to maintain and expand its competitive moat beyond its current proprietary data and AI foundation models?”

  • 2

    “With current recognized revenue at ~$8M but over $1Bn in potential partnership value, what is the company's strategy for converting these partnerships into consistent, high-margin revenue streams and managing the very high capital intensity required for drug development?”

  • 3

    “Considering the Series A funding in 2022 and the typical long timelines in drug discovery, what is the anticipated timeline for a liquidity event (e.g., IPO or acquisition) for employees, and how does the company plan to manage potential dilution from future funding rounds?”

Community

Valuation Sentiment

Our model estimates -64% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.